Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EP 0042 - Ellipses Pharma

Next Previous
Drug Profile

EP 0042 - Ellipses Pharma

Alternative Names: EP0042

Latest Information Update: 02 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Institute of Cancer Research
  • Developer Ellipses Pharma
  • Class Antineoplastics
  • Mechanism of Action Aurora kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 07 Dec 2024 Efficacy, pharmacokinetics and adverse event data from a phase I/II trial in Acute myeloid leukemia, Myelodysplastic syndromes and Chronic myelomonocytic leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 09 Dec 2023 Updated efficacy and adverse event data from a Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 14 Mar 2023 EP 0042 - Ellipses Pharma receives Orphan Drug status for Acute myeloid leukaemia in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top